Kairos Pharma, Ltd. KAPA 深 滬
已收盤 04-02 16:00:00 美东时间
0.5811
+0.002
+0.40%
華盛通- 最 高0.60
- 今 開0.60
- 成交量 7.65万股
- 最 低 0.5566
- 昨 收 0.5788
- 總市值 1209.93万
- 52周最高 2.11
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 0.40
- 委 比 0.00%
- 總股本 2082.14万
- 歷史最高 4.00
- 量 比 1.24
- 振 幅 7.50%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate
Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same
04-01 06:37
Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates, Financial Terms Undisclosed
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn
02-26 20:14
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
2025-11-04 22:30
Kairos Pharma Approves RSUs and Cash Bonuses
Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On October 8, 2025,...
2025-10-16 04:28
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
2025-09-22 18:44
Kairos Pharma Announces Efficacy Data From Ongoing Phase 2 Clinical Trial Of ENV105 In Patients With Metastatic Castration-Resistant Prostate Cancer
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety dataCompany to host virtual KOL discussion today to provide additional perspective on data
2025-09-18 20:05
Kairos Pharma Presents Phase 1 Data at Conference
Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On September 3, 202...
2025-09-03 20:48
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market t...
2025-09-02 17:28
